tranexamic acid has been researched along with Hematoma in 64 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Hematoma: A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Tranexamic acid (TXA) is an antifibrinolytic drug potentially limiting hematoma expansion." | 9.69 | Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial. ( Barinka, F; Baumgartner, P; Bonati, LH; De Marchis, GM; Engelter, ST; Fischer, U; Gensicke, H; Guzman, R; Kägi, G; Karwacki, GM; Lyrer, PA; Maurer, M; Nedeltchev, K; Nickel, CH; Peters, N; Polymeris, AA; Schaedelin, S; Seiffge, DJ; Siepen, BM; Sprigg, N; Stippich, C; Thilemann, S; Traenka, C; Tsakiris, DA; Vehoff, J; Wagner, B; Wegener, S; Z'Graggen, WJ, 2023) |
| "This study aims to illustrate the impact of applying the tranexamic acid impregnated in a gelatin sponge between the anterior rectus sheath and the Rectus Abdominis muscle during Cesarean section (CS) in minimizing rectus sheath hematoma (RHS) in women treated with Warfarin." | 9.69 | Role of tranexamic acid-soaked gelatin sponge in minimizing rectus sheath hematoma after cesarean section in women treated with warfarin, a simple tool for high-risk cases, a randomized controlled trial. ( Hany, A; Mansour, A; Nabil, M; Sediek, M, 2023) |
| "This prospective nested magnetic resonance imaging (MRI) substudy of a randomized clinical trial (RCT) recruited participants from the multicenter, double-blind, placebo-controlled, phase 3 RCT (Tranexamic Acid for Hyperacute Primary Intracerebral Hemorrhage [TICH-2]) from July 1, 2015, to September 30, 2017, and conducted follow-up to 90 days after participants were randomized to either the tranexamic acid or placebo group." | 9.51 | Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial. ( Al-Shahi Salman, R; Bath, PM; Casado, AM; Dineen, RA; England, TJ; Gallagher, R; Law, ZK; Morgan, PS; Pszczolkowski, S; Roberts, I; Sprigg, N; Swienton, D; Werring, DJ; Woodhouse, LJ, 2022) |
| "Evidence-based medicine was used to evaluate the efficacy and safety of tranexamic acid in patients with intracerebral hemorrhage." | 9.41 | Tranexamic acid in intracerebral hemorrhage: a meta-analysis. ( Ling, L; Yu, Z, 2023) |
| "Data from the TICH-2 trial do not support that admission spot sign status modifies the treatment effect of tranexamic acid versus placebo in patients with acute intracerebral hemorrhage." | 9.41 | Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. ( Bath, PM; Christensen, H; Christensen, LM; Dineen, RA; Flaherty, K; Gluud, C; Jakobsen, JC; Law, Z; Overgaard, K; Ovesen, C; Rasmussen, RS; Sprigg, N; Steiner, T, 2021) |
| "The effects of tranexamic acid on spontaneous intracerebral hemorrhage in reducing hematoma expansion and mortality as well as its role in thromboembolic complications and in the improvement of functional outcomes remain substantially uncertain." | 9.12 | Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysis. ( Ma, L; Song, J; Wang, X; You, C, 2021) |
| "A randomized double-blind trial has shown that, in 160 women with breast cancer undergoing lumpectomy or mastectomy with axillary clearance, perioperative and postoperative administration of tranexamic acid 1 g three times daily resulted in a significant reduction in the mean postoperative drainage volume compared with patients given placebo (283 versus 432 ml, P < 0." | 9.07 | Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. ( Haberthuer, F; Harder, F; Kreuter, U; Laffer, U; Oertli, D, 1994) |
| "Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction." | 7.96 | Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020) |
| "prothrombin complex concentrate and fresh-frozen plasma effectively prevent hematoma growth in murine warfarin-associated intracerebral hemorrhage, whereas Factor VIIa was less effective." | 7.77 | Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. ( Heiland, S; Illanes, S; Schwarting, S; Veltkamp, R; Zhou, W, 2011) |
| "No tranexamic acid was administered to the control group." | 7.30 | [Effects of Tranexamic Acid on Perioperative Blood Loss and Wound Hematoma Development in Lumbar Spine Surgery: a Prospective Randomized Study]. ( Hrabálek, L; Jablonský, J; Novák, V; Stejskal, P; Trnka, Š; Wanek, T, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent, which has shown an effect on reducing blood loss in many diseases." | 6.72 | Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials. ( Chen, Z; Gao, B; Rong, X; Wang, Z; Xue, T; Yang, Y, 2021) |
| "The use of IV TXA is a safe and effective way to reduce hematoma rates in patients receiving reduction mammoplasty." | 5.91 | The Usage of Intravenous Tranexamic Acid in Reduction Mammaplasty Safely Reduces Hematoma Rates. ( Kebede, S; Losken, A; Marxen, T; Om, A, 2023) |
| "Tranexamic acid (TXA) has gained increasing recognition as a valuable pharmacologic agent within plastic surgery." | 5.72 | Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty. ( Alsayed, A; Antezana, L; Banuelos, J; Curiel, D; Harless, CA; Kerivan, L; Kuruoglu, D; Martinez-Jorge, J; Nguyen, MT; Sharaf, BA; Tran, NV; Vijayasekaran, A; Weissler, JM, 2022) |
| "In this trial, the median size of post-kidney biopsy hematoma was unexpectedly larger in the high-dose tranexamic acid group than in the placebo group." | 5.69 | Intravenous Tranexamic Acid in Percutaneous Kidney Biopsy: A Randomized Controlled Trial. ( Izawa, J; Katsuren, M; Kawamura, T; Matsuzaki, K; Miyasato, H; Nishioka, N; Ohigashi, T; Raita, Y; Sozu, T; Sudo, K; Uehara, G; Yano, H, 2023) |
| " Tranexamic acid (TXA) is an antifibrinolytic drug potentially limiting hematoma expansion." | 5.69 | Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial. ( Barinka, F; Baumgartner, P; Bonati, LH; De Marchis, GM; Engelter, ST; Fischer, U; Gensicke, H; Guzman, R; Kägi, G; Karwacki, GM; Lyrer, PA; Maurer, M; Nedeltchev, K; Nickel, CH; Peters, N; Polymeris, AA; Schaedelin, S; Seiffge, DJ; Siepen, BM; Sprigg, N; Stippich, C; Thilemann, S; Traenka, C; Tsakiris, DA; Vehoff, J; Wagner, B; Wegener, S; Z'Graggen, WJ, 2023) |
| "This study aims to illustrate the impact of applying the tranexamic acid impregnated in a gelatin sponge between the anterior rectus sheath and the Rectus Abdominis muscle during Cesarean section (CS) in minimizing rectus sheath hematoma (RHS) in women treated with Warfarin." | 5.69 | Role of tranexamic acid-soaked gelatin sponge in minimizing rectus sheath hematoma after cesarean section in women treated with warfarin, a simple tool for high-risk cases, a randomized controlled trial. ( Hany, A; Mansour, A; Nabil, M; Sediek, M, 2023) |
| "Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units (STOP-MSU) is a phase II double-blind, randomised, placebo-controlled, multicentre, international investigator-led clinical trial, conducted within the estimand statistical framework." | 5.51 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial. ( Brown, H; Campbell, BCV; Cheung, A; Cho, DY; Choi, P; Churilov, L; Clissold, B; Cloud, GC; Dang, DP; Davis, SM; Donnan, GA; Grimley, R; Hsu, CY; Jeng, JS; Kleinig, T; Levi, C; Ma, H; Mahawish, K; Meretoja, A; Mitchell, PJ; Nguyen, HT; Parsons, MW; Phuong, NTM; Ranta, A; Sanders, L; Shah, D; Sharma, G; Spratt, N; Ton, MD; Wang, HK; Worthington, J; Wu, T; Yan, B; Yassi, N; Yogendrakumar, V; Zhao, H, 2022) |
| "This prospective nested magnetic resonance imaging (MRI) substudy of a randomized clinical trial (RCT) recruited participants from the multicenter, double-blind, placebo-controlled, phase 3 RCT (Tranexamic Acid for Hyperacute Primary Intracerebral Hemorrhage [TICH-2]) from July 1, 2015, to September 30, 2017, and conducted follow-up to 90 days after participants were randomized to either the tranexamic acid or placebo group." | 5.51 | Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial. ( Al-Shahi Salman, R; Bath, PM; Casado, AM; Dineen, RA; England, TJ; Gallagher, R; Law, ZK; Morgan, PS; Pszczolkowski, S; Roberts, I; Sprigg, N; Swienton, D; Werring, DJ; Woodhouse, LJ, 2022) |
| "Evidence-based medicine was used to evaluate the efficacy and safety of tranexamic acid in patients with intracerebral hemorrhage." | 5.41 | Tranexamic acid in intracerebral hemorrhage: a meta-analysis. ( Ling, L; Yu, Z, 2023) |
| "Data from the TICH-2 trial do not support that admission spot sign status modifies the treatment effect of tranexamic acid versus placebo in patients with acute intracerebral hemorrhage." | 5.41 | Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. ( Bath, PM; Christensen, H; Christensen, LM; Dineen, RA; Flaherty, K; Gluud, C; Jakobsen, JC; Law, Z; Overgaard, K; Ovesen, C; Rasmussen, RS; Sprigg, N; Steiner, T, 2021) |
| "To determine the effect of Intravenous Tranexamic Acid (TXA) on traumatic intracerebral hemorrhage." | 5.41 | Effect of Intravenous Tranexamic Acid on Intracerebral Brain Hemorrhage in Traumatic Brain Injury. ( Farrahi, P; Marandi, HJ; Rasras, S; Safari, H; Zeinali, M, 2021) |
| "Systemic administration of TXA can effectively reduce the postoperative blood loss which results in lower rate of transfusion requirement and wound hematoma in minimally invasive TKA patients when rivaroxaban is used for thromboprophylaxis." | 5.24 | The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial. ( Chen, B; Huang, CC; Kuo, FC; Lin, PC; Wang, JW; Yen, SH, 2017) |
| "Our study showed no clinical benefit or disadvantage to closed suction drainage in anterior hip arthroplasty with the concomitant use of tranexamic acid for surgical hemostasis and aspirin for venous thromboembolism prophylaxis." | 5.22 | Closed Suction Drainage Has No Benefits in Anterior Hip Arthroplasty: A Prospective, Randomized Trial. ( Barksdale, LC; Calvo, C; McNamara, CA; Patel, PD; Suarez, JC; Szubski, CR, 2016) |
| "This is the first trial to evaluate the efficacy of tranexamic acid in intracerebral hemorrhage patients selected based on an imaging biomarker of high likelihood of hematoma growth." | 5.19 | The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. ( Anderson, CS; Aviv, RI; Barras, C; Bladin, C; Campbell, BC; Churilov, L; Davis, SM; Delcourt, C; Donnan, GA; Jannes, J; Kleinig, T; Lee, A; Levi, C; Mahant, N; Markus, R; Meretoja, A; Mitchell, P; Nandurkar, H; Parsons, MW; Rupasinghe, J; Spratt, NJ; Sturm, J; Wijeratne, T; Yan, B; Yassi, N; Zavala, J, 2014) |
| "The effects of tranexamic acid on spontaneous intracerebral hemorrhage in reducing hematoma expansion and mortality as well as its role in thromboembolic complications and in the improvement of functional outcomes remain substantially uncertain." | 5.12 | Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysis. ( Ma, L; Song, J; Wang, X; You, C, 2021) |
| "A randomized double-blind trial has shown that, in 160 women with breast cancer undergoing lumpectomy or mastectomy with axillary clearance, perioperative and postoperative administration of tranexamic acid 1 g three times daily resulted in a significant reduction in the mean postoperative drainage volume compared with patients given placebo (283 versus 432 ml, P < 0." | 5.07 | Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. ( Haberthuer, F; Harder, F; Kreuter, U; Laffer, U; Oertli, D, 1994) |
| "The purpose of this study was to explore efficacy of locally injected tranexamic acid (TXA) at a concentration of 1 mg/mL for reduction perioperative bleeding and postoperative complications in subcutaneous tumor excisions." | 4.31 | Efficacy of local infiltration of tranexamic acid in subcutaneous surgery: A protocol from a single medical center. ( Chang, YJ; Lin, HC; Lin, YH; Wang, PL, 2023) |
| "Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction." | 3.96 | Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020) |
| "prothrombin complex concentrate and fresh-frozen plasma effectively prevent hematoma growth in murine warfarin-associated intracerebral hemorrhage, whereas Factor VIIa was less effective." | 3.77 | Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. ( Heiland, S; Illanes, S; Schwarting, S; Veltkamp, R; Zhou, W, 2011) |
| "No tranexamic acid was administered to the control group." | 3.30 | [Effects of Tranexamic Acid on Perioperative Blood Loss and Wound Hematoma Development in Lumbar Spine Surgery: a Prospective Randomized Study]. ( Hrabálek, L; Jablonský, J; Novák, V; Stejskal, P; Trnka, Š; Wanek, T, 2023) |
| "Its role in reducing postoperative blood loss in breast surgery remains unclear." | 3.01 | The Effects of Tranexamic Acid in Breast Surgery: A Systematic Review and Meta-Analysis. ( Huynh, MNQ; McRae, MC; McRae, MH; Voineskos, S; Wong, CR, 2023) |
| "Data from the Tranexamic acid in IntraCerebral Hemorrhage-2 (TICH-2) randomized controlled trial were analyzed." | 3.01 | Predictors and Outcomes of Neurological Deterioration in Intracerebral Hemorrhage: Results from the TICH-2 Randomized Controlled Trial. ( Appleton, JP; Bath, PM; Bereczki, D; Cala, L; Ciccone, A; Dineen, R; England, TJ; Law, ZK; Mistri, AK; Ozturk, S; Sprigg, N, 2021) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent, which has shown an effect on reducing blood loss in many diseases." | 2.72 | Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials. ( Chen, Z; Gao, B; Rong, X; Wang, Z; Xue, T; Yang, Y, 2021) |
| "Tranexamic acid was given at the end of the operation and 3 hours later." | 2.69 | Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. ( Benoni, G; Fredin, H; Lethagen, S; Nilsson, P, 2000) |
| "The use of IV TXA is a safe and effective way to reduce hematoma rates in patients receiving reduction mammoplasty." | 1.91 | The Usage of Intravenous Tranexamic Acid in Reduction Mammaplasty Safely Reduces Hematoma Rates. ( Kebede, S; Losken, A; Marxen, T; Om, A, 2023) |
| "Tranexamic acid (TXA) has shown to significantly reduce perioperative blood loss in elective orthopedic joint replacement surgery but is yet not implemented in acute hip fracture surgery for elderly patients who are particularly vulnerable to perioperative blood loss and postoperative anemia." | 1.72 | Clinical outcomes of tranexamic acid in acute hip hemiarthroplasties in frail geriatric patients. ( de Jong, L; Kuijper, TM; Roukema, GR; van Rijckevorsel, VAJIM, 2022) |
| "Tranexamic acid (TXA) has gained increasing recognition as a valuable pharmacologic agent within plastic surgery." | 1.72 | Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty. ( Alsayed, A; Antezana, L; Banuelos, J; Curiel, D; Harless, CA; Kerivan, L; Kuruoglu, D; Martinez-Jorge, J; Nguyen, MT; Sharaf, BA; Tran, NV; Vijayasekaran, A; Weissler, JM, 2022) |
| "Acquired haemophilia A is a rare but important diagnosis, carrying a mortality rate of 22%." | 1.56 | ( Howden, WB; Kam, J; Leith, N; Singh, S, 2020) |
| "A young girl with constant exotropia was planned for surgery." | 1.51 | Factor XIII deficiency leading to preseptal haematoma post-strabismus surgery. ( Badakere, A; Jain, M; Kekunnaya, R, 2019) |
| "Fibrinogen level was normalized within two days (2." | 1.43 | Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report. ( Cvetković, Z; Kulić, A; Libek, V, 2016) |
| "Glanzmann's thrombasthenia (GT) is a very rare autosomal recessive genetic bleeding disorder." | 1.38 | Giant abdominopelvic haematoma arising from ovulation in a Glanzmann's thrombasthenia patient with platelet refractoriness: treatment with surgery and intra-abdominal tranexamic acid. ( Bektas, O; Boyraz, G; Buyukasik, Y; Selcuk Tuncer, Z; Selcuk, I, 2012) |
| "Immediately after diagnosis of intracerebral hemorrhage on computed tomographic scan, 156 patients who were admitted within 24 hours of onset were treated with either a combination of PAF and BPC (PAF group) or a combination of RAF and BPC (RAF group)." | 1.33 | Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. ( Fujii, Y; Morita, K; Sorimachi, T; Tanaka, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.13) | 18.7374 |
| 1990's | 5 (7.81) | 18.2507 |
| 2000's | 7 (10.94) | 29.6817 |
| 2010's | 15 (23.44) | 24.3611 |
| 2020's | 35 (54.69) | 2.80 |
| Authors | Studies |
|---|---|
| Laikhter, E | 1 |
| Comer, CD | 1 |
| Shiah, E | 1 |
| Manstein, SM | 1 |
| Bain, PA | 1 |
| Lin, SJ | 1 |
| Wang, X | 2 |
| Ma, L | 1 |
| Song, J | 1 |
| You, C | 1 |
| Yassi, N | 2 |
| Zhao, H | 1 |
| Churilov, L | 2 |
| Campbell, BCV | 1 |
| Wu, T | 1 |
| Ma, H | 1 |
| Cheung, A | 1 |
| Kleinig, T | 2 |
| Brown, H | 1 |
| Choi, P | 1 |
| Jeng, JS | 1 |
| Ranta, A | 1 |
| Wang, HK | 1 |
| Cloud, GC | 1 |
| Grimley, R | 1 |
| Shah, D | 1 |
| Spratt, N | 1 |
| Cho, DY | 1 |
| Mahawish, K | 1 |
| Sanders, L | 1 |
| Worthington, J | 1 |
| Clissold, B | 1 |
| Meretoja, A | 2 |
| Yogendrakumar, V | 1 |
| Ton, MD | 1 |
| Dang, DP | 1 |
| Phuong, NTM | 1 |
| Nguyen, HT | 1 |
| Hsu, CY | 1 |
| Sharma, G | 1 |
| Mitchell, PJ | 1 |
| Yan, B | 2 |
| Parsons, MW | 2 |
| Levi, C | 2 |
| Donnan, GA | 2 |
| Davis, SM | 2 |
| Albanese, R | 1 |
| Zingaretti, N | 1 |
| Almesberger, D | 1 |
| Parodi, PC | 1 |
| Weissler, JM | 2 |
| Kuruoglu, D | 1 |
| Antezana, L | 1 |
| Curiel, D | 1 |
| Kerivan, L | 1 |
| Alsayed, A | 1 |
| Banuelos, J | 2 |
| Harless, CA | 2 |
| Sharaf, BA | 1 |
| Vijayasekaran, A | 1 |
| Martinez-Jorge, J | 2 |
| Tran, NV | 2 |
| Nguyen, MT | 2 |
| van Rijckevorsel, VAJIM | 1 |
| Roukema, GR | 1 |
| Kuijper, TM | 1 |
| de Jong, L | 1 |
| Pszczolkowski, S | 2 |
| Sprigg, N | 6 |
| Woodhouse, LJ | 1 |
| Gallagher, R | 1 |
| Swienton, D | 1 |
| Law, ZK | 3 |
| Casado, AM | 1 |
| Roberts, I | 1 |
| Werring, DJ | 1 |
| Al-Shahi Salman, R | 1 |
| England, TJ | 3 |
| Morgan, PS | 1 |
| Bath, PM | 5 |
| Dineen, RA | 4 |
| Fernau, J | 1 |
| Zhang, Z | 2 |
| Guan, X | 1 |
| Li, Z | 1 |
| Xin, M | 1 |
| Izawa, J | 1 |
| Matsuzaki, K | 1 |
| Raita, Y | 1 |
| Uehara, G | 1 |
| Nishioka, N | 1 |
| Yano, H | 1 |
| Sudo, K | 1 |
| Katsuren, M | 1 |
| Ohigashi, T | 1 |
| Sozu, T | 1 |
| Kawamura, T | 1 |
| Miyasato, H | 1 |
| Baker, DM | 1 |
| Jacob, L | 1 |
| Busuttil, A | 1 |
| Ye, L | 1 |
| Guan, J | 1 |
| Chen, X | 1 |
| Lu, H | 1 |
| Xiao, Y | 1 |
| Dai, X | 1 |
| Wu, M | 1 |
| Ma, S | 1 |
| Sun, X | 1 |
| Li, L | 1 |
| Tan, Y | 2 |
| Xia, Y | 1 |
| Calpin, GG | 1 |
| McAnena, PF | 1 |
| Davey, MG | 1 |
| Calpin, P | 1 |
| Kerin, MJ | 1 |
| McInerney, N | 1 |
| Walsh, SR | 1 |
| Lowery, AJ | 1 |
| Liechti, R | 1 |
| van de Wall, BJM | 1 |
| Hug, U | 1 |
| Fritsche, E | 1 |
| Franchi, A | 1 |
| Om, A | 1 |
| Marxen, T | 1 |
| Kebede, S | 1 |
| Losken, A | 1 |
| Safran, T | 1 |
| Vorstenbosch, J | 1 |
| Viezel-Mathieu, A | 1 |
| Davison, P | 1 |
| Dionisopoulos, T | 1 |
| Huynh, MNQ | 1 |
| Wong, CR | 1 |
| McRae, MC | 1 |
| Voineskos, S | 1 |
| McRae, MH | 1 |
| Sipos, K | 1 |
| Kämäräinen, S | 1 |
| Kauhanen, S | 1 |
| Stejskal, P | 1 |
| Trnka, Š | 1 |
| Hrabálek, L | 1 |
| Wanek, T | 1 |
| Jablonský, J | 1 |
| Novák, V | 1 |
| Polymeris, AA | 1 |
| Karwacki, GM | 1 |
| Siepen, BM | 1 |
| Schaedelin, S | 1 |
| Tsakiris, DA | 1 |
| Stippich, C | 1 |
| Guzman, R | 1 |
| Nickel, CH | 1 |
| Kägi, G | 1 |
| Vehoff, J | 1 |
| Barinka, F | 1 |
| Thilemann, S | 1 |
| Maurer, M | 1 |
| Wagner, B | 1 |
| Traenka, C | 1 |
| Gensicke, H | 1 |
| De Marchis, GM | 1 |
| Bonati, LH | 1 |
| Fischer, U | 1 |
| Z'Graggen, WJ | 1 |
| Nedeltchev, K | 1 |
| Wegener, S | 1 |
| Baumgartner, P | 1 |
| Engelter, ST | 1 |
| Seiffge, DJ | 1 |
| Peters, N | 1 |
| Lyrer, PA | 1 |
| Chang, YJ | 1 |
| Lin, YH | 1 |
| Wang, PL | 1 |
| Lin, HC | 1 |
| Hany, A | 1 |
| Mansour, A | 1 |
| Sediek, M | 1 |
| Nabil, M | 1 |
| Jain, M | 1 |
| Kekunnaya, R | 1 |
| Badakere, A | 1 |
| Ali, A | 1 |
| Krishnan, K | 1 |
| Bischoff, A | 1 |
| Appleton, JP | 2 |
| Scutt, P | 1 |
| Woodhouse, L | 1 |
| Cala, LA | 1 |
| Ozturk, S | 2 |
| Roffe, C | 1 |
| Bereczki, D | 2 |
| Ciccone, A | 2 |
| Christensen, H | 3 |
| Ovesen, C | 3 |
| Howden, WB | 1 |
| Kam, J | 1 |
| Leith, N | 1 |
| Singh, S | 1 |
| Jacobson, SR | 1 |
| Manrique, OJ | 1 |
| Myckatyn, TM | 1 |
| Tenenbaum, MM | 1 |
| Dineen, R | 1 |
| Cala, L | 1 |
| Mistri, AK | 1 |
| Jiang, C | 1 |
| Wang, J | 2 |
| Zhang, J | 1 |
| Gao, B | 1 |
| Xue, T | 1 |
| Rong, X | 1 |
| Yang, Y | 1 |
| Wang, Z | 2 |
| Chen, Z | 1 |
| Hayward, CPM | 1 |
| Tasneem, S | 1 |
| Rivard, GE | 1 |
| Safari, H | 1 |
| Farrahi, P | 1 |
| Rasras, S | 1 |
| Marandi, HJ | 1 |
| Zeinali, M | 1 |
| Burton, H | 1 |
| Mossadegh, S | 1 |
| McCarthy, R | 1 |
| Liu, J | 1 |
| Nie, X | 1 |
| Gu, H | 1 |
| Zhou, Q | 1 |
| Sun, H | 1 |
| Liu, D | 1 |
| Zheng, L | 1 |
| Zhao, J | 1 |
| Wang, Y | 2 |
| Cao, Y | 1 |
| Zhu, H | 1 |
| Zhang, Y | 1 |
| Yi, L | 1 |
| Pu, Y | 1 |
| Wen, M | 1 |
| Yang, Z | 1 |
| Sun, S | 1 |
| Wang, W | 1 |
| Zhao, X | 1 |
| Liu, L | 1 |
| Jakobsen, JC | 2 |
| Gluud, C | 2 |
| Steiner, T | 2 |
| Law, Z | 2 |
| Flaherty, K | 2 |
| Christensen, LM | 1 |
| Overgaard, K | 1 |
| Rasmussen, RS | 1 |
| Yu, Z | 1 |
| Ling, L | 1 |
| Kulić, A | 1 |
| Cvetković, Z | 1 |
| Libek, V | 1 |
| Donnan, G | 1 |
| Davis, S | 1 |
| Jiang, W | 1 |
| Shang, L | 1 |
| Knight, H | 1 |
| Banks, J | 1 |
| Muchmore, J | 1 |
| Ives, C | 1 |
| Green, M | 1 |
| Campbell, BC | 1 |
| Aviv, RI | 1 |
| Barras, C | 1 |
| Mitchell, P | 1 |
| Nandurkar, H | 1 |
| Bladin, C | 1 |
| Wijeratne, T | 1 |
| Spratt, NJ | 1 |
| Jannes, J | 1 |
| Sturm, J | 1 |
| Rupasinghe, J | 1 |
| Zavala, J | 1 |
| Lee, A | 1 |
| Markus, R | 1 |
| Delcourt, C | 1 |
| Mahant, N | 1 |
| Anderson, CS | 1 |
| Remérand, F | 2 |
| Cotten, M | 1 |
| N'Guessan, YF | 1 |
| Couvret, C | 2 |
| Rosset, P | 2 |
| Favard, L | 1 |
| Laffon, M | 2 |
| Fusciardi, J | 2 |
| Fisher, C | 1 |
| Mo, A | 1 |
| Warrillow, S | 1 |
| Smith, C | 1 |
| Jones, D | 1 |
| Suarez, JC | 1 |
| McNamara, CA | 1 |
| Barksdale, LC | 1 |
| Calvo, C | 1 |
| Szubski, CR | 1 |
| Patel, PD | 1 |
| Beton, O | 1 |
| Saricam, E | 1 |
| Kaya, H | 1 |
| Yucel, H | 1 |
| Dogdu, O | 1 |
| Turgut, OO | 1 |
| Berkan, O | 1 |
| Tandogan, I | 1 |
| Yilmaz, MB | 1 |
| Wang, JW | 1 |
| Chen, B | 1 |
| Lin, PC | 1 |
| Yen, SH | 1 |
| Huang, CC | 1 |
| Kuo, FC | 1 |
| Amissah-Arthur, KN | 1 |
| Groppe, M | 1 |
| Scotcher, S | 1 |
| Illanes, S | 1 |
| Zhou, W | 1 |
| Schwarting, S | 1 |
| Heiland, S | 1 |
| Veltkamp, R | 1 |
| Chevet, I | 1 |
| Baud, A | 1 |
| Pouplard, C | 1 |
| Buyukasik, Y | 1 |
| Boyraz, G | 1 |
| Selcuk, I | 1 |
| Bektas, O | 1 |
| Selcuk Tuncer, Z | 1 |
| Yasui, H | 1 |
| Adachi, Y | 1 |
| Minami, T | 1 |
| Ishida, T | 1 |
| Kato, Y | 1 |
| Imai, K | 1 |
| Sorimachi, T | 1 |
| Fujii, Y | 1 |
| Morita, K | 1 |
| Tanaka, R | 1 |
| Coetzee, MJ | 1 |
| Hoshino, Y | 1 |
| Hatake, K | 1 |
| Muroi, K | 1 |
| Tsunoda, S | 1 |
| Suzuki, T | 1 |
| Miwa, A | 1 |
| Sakamoto, S | 1 |
| Miura, Y | 1 |
| Oertli, D | 1 |
| Laffer, U | 1 |
| Haberthuer, F | 1 |
| Kreuter, U | 1 |
| Harder, F | 1 |
| Miyauchi, Y | 2 |
| Mii, Y | 2 |
| Aoki, M | 1 |
| Tamai, S | 2 |
| Takahashi, Y | 2 |
| Yoshioka, A | 2 |
| Panula, K | 1 |
| Oikarinen, K | 1 |
| Vujkovac, B | 1 |
| Sabovic, M | 1 |
| Benoni, G | 1 |
| Lethagen, S | 1 |
| Nilsson, P | 1 |
| Fredin, H | 1 |
| van Rijn, RS | 1 |
| Verdonck, LF | 1 |
| Tanaka, T | 1 |
| Nakajima, N | 1 |
| Fukui, H | 1 |
| Takahashi, H | 1 |
| Koike, T | 1 |
| Yoshida, N | 1 |
| Kitahara, O | 1 |
| Hanano, M | 1 |
| Shibata, A | 1 |
| Aoki, N | 1 |
| Pickard, JD | 1 |
| Walker, V | 1 |
| Vile, J | 1 |
| Perry, S | 1 |
| Smythe, PJ | 1 |
| Hunt, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514] | Phase 4 | 98 participants (Actual) | Interventional | 2021-10-29 | Completed | ||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Efficacy of Tranexamic Acid in Femoral Shaft Fractures Osteosynthesis; A Double Blind Randomized Controlled Trial[NCT04803591] | Phase 4 | 0 participants (Actual) | Interventional | 2021-08-01 | Withdrawn (stopped due to Not approved by Ethics Commettee) | ||
| Effects of Tranexamic Acid for Alloplastic Breast Reconstruction: A Randomized Control Trial[NCT04918589] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage[NCT05836831] | Phase 4 | 3,400 participants (Anticipated) | Interventional | 2022-08-30 | Recruiting | ||
| STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.[NCT01702636] | Phase 2 | 100 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Benefits on Post-operative Pain of Intravenous, Intraoperative, Tranexamic Acid Injection During Arthroscopic Shoulder Surgery.[NCT05302986] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-02-24 | Recruiting | ||
| Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma[NCT00307606] | Phase 4 | 40 participants (Anticipated) | Interventional | 2005-12-31 | Recruiting | ||
| Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial[NCT02615366] | Phase 4 | 800 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty[NCT00375440] | 0 participants (Actual) | Interventional | 2005-02-28 | Withdrawn (stopped due to Study halted prematurely as investigator left the institution.) | |||
| Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion[NCT03923959] | Phase 3 | 400 participants (Anticipated) | Interventional | 2020-02-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days
| Intervention | breasts (Number) |
|---|---|
| Treatment Side (Right or Left) | 2 |
| Placebo Side (Right or Left) | 1 |
The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
8 reviews available for tranexamic acid and Hematoma
| Article | Year |
|---|---|
A Systematic Review and Meta-Analysis Evaluating the Impact of Tranexamic Acid Administration in Aesthetic Plastic Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Female; Hematoma; Humans; Surgery, Plasti | 2022 |
Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Cerebral Hemorrhage; Hematoma; Humans; Randomized Controlled Trials | 2021 |
The role of tranexamic acid in reducing post-operative bleeding and seroma formation in breast surgery: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Seroma; T | 2023 |
Tranexamic Acid Use in Breast Surgery: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Mastectom | 2023 |
The Effects of Tranexamic Acid in Breast Surgery: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Postopera | 2023 |
Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials.
Topics: Antifibrinolytic Agents; Brain Hemorrhage, Traumatic; Cerebral Hemorrhage; Disease Progression; Hema | 2021 |
Tranexamic acid in intracerebral hemorrhage: a meta-analysis.
Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Cohort Studies; Hematoma; Humans; Randomized Controlle | 2023 |
Tranexamic acid can reduce blood loss in patients undergoing intertrochanteric fracture surgery: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hematoma; Hemoglobins; Hip Fractur | 2019 |
20 trials available for tranexamic acid and Hematoma
| Article | Year |
|---|---|
Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial.
Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Clinical Trials, Phase II as Topic; Hematoma; Humans; | 2022 |
Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial.
Topics: Aged; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-Blind Method; Female; Hematoma; Humans; I | 2022 |
Intravenous Tranexamic Acid in Percutaneous Kidney Biopsy: A Randomized Controlled Trial.
Topics: Adult; Antifibrinolytic Agents; Biopsy; Double-Blind Method; Hematoma; Humans; Kidney; Tranexamic Ac | 2023 |
Topics: Aged; Antifibrinolytic Agents; Arthrodesis; Blood Loss, Surgical; Bone Screws; Fracture Fixation, In | 2022 |
Topical Tranexamic Acid in Breast Reconstruction: A Double-Blind Randomized Controlled Trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Breast Ne | 2023 |
[Effects of Tranexamic Acid on Perioperative Blood Loss and Wound Hematoma Development in Lumbar Spine Surgery: a Prospective Randomized Study].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hematoma; Humans; Postoperative Hemorrhage; Prospecti | 2023 |
Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Cerebral Hemorrhag | 2023 |
Role of tranexamic acid-soaked gelatin sponge in minimizing rectus sheath hematoma after cesarean section in women treated with warfarin, a simple tool for high-risk cases, a randomized controlled trial.
Topics: Anticoagulants; Cesarean Section; Female; Gelatin; Hematoma; Heparin; Heparin, Low-Molecular-Weight; | 2023 |
Predictors and Outcomes of Neurological Deterioration in Intracerebral Hemorrhage: Results from the TICH-2 Randomized Controlled Trial.
Topics: Aged; Cerebral Hemorrhage; Hematoma; Humans; Logistic Models; Male; Tranexamic Acid | 2021 |
Rationale and Design of a Randomized, Double-Blind Trial Evaluating the Efficacy of Tranexamic Acid on Hematoma Expansion and Peri-hematomal Edema in Patients with Spontaneous Intracerebral Hemorrhage within 4.5 h after Symptom Onset: The THE-ICH Trial Pr
Topics: Antifibrinolytic Agents; Brain Edema; Cerebral Hemorrhage; China; Disease Progression; Double-Blind | 2020 |
Effect of Intravenous Tranexamic Acid on Intracerebral Brain Hemorrhage in Traumatic Brain Injury.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antifibrinolytic Agents; Brain Injuries, Traum | 2021 |
Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment (TRAIGE): a multicentre, randomised, placebo-controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Cerebral Hemorrhage; Female; Hematoma; Humans; Male; Middle Ag | 2021 |
Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Angiography; Cerebral Hemorrhage; Compute | 2021 |
Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial.
Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Data Interpretation, Statistical; Disease Progression; | 2018 |
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Australia; Cerebral Angiography; Cerebral Hemorrhage; Contrast | 2014 |
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Australia; Cerebral Angiography; Cerebral Hemorrhage; Contrast | 2014 |
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Australia; Cerebral Angiography; Cerebral Hemorrhage; Contrast | 2014 |
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Australia; Cerebral Angiography; Cerebral Hemorrhage; Contrast | 2014 |
Closed Suction Drainage Has No Benefits in Anterior Hip Arthroplasty: A Prospective, Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2016 |
The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2017 |
[Tranexamic acid reduces haematomas but not pain after total knee arthroplasty].
Topics: Aged; Anesthesia, General; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Female; Hematom | 2011 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
36 other studies available for tranexamic acid and Hematoma
| Article | Year |
|---|---|
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Antifibrinolytic Agents; Hematoma; Humans; Mammaplasty; Thromboembolism; Tranexamic Acid | 2022 |
Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hematoma; Humans | 2022 |
Clinical outcomes of tranexamic acid in acute hip hemiarthroplasties in frail geriatric patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Frail Elderly; | 2022 |
Commentary on: Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty.
Topics: Female; Hematoma; Humans; Mammaplasty; Seroma; Tranexamic Acid | 2022 |
Thoughts on: Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty.
Topics: Female; Hematoma; Humans; Mammaplasty; Seroma; Tranexamic Acid | 2022 |
A Stepwise Haemostasis Intraoperative Protocol Driven Reduction of Haematoma Rate Following Symptomatic Carotidendarterectomy.
Topics: Carotid Stenosis; Endarterectomy, Carotid; Hematoma; Hemostasis; Humans; Protamines; Risk Factors; S | 2023 |
The Usage of Intravenous Tranexamic Acid in Reduction Mammaplasty Safely Reduces Hematoma Rates.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hematoma; Humans; Mammaplasty; Retrospective | 2023 |
Topical tranexamic acid reduces postoperative hematomas in reduction mammaplasties.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Cohort Stu | 2023 |
Efficacy of local infiltration of tranexamic acid in subcutaneous surgery: A protocol from a single medical center.
Topics: Fibrinolytic Agents; Hematoma; Humans; Postoperative Complications; Retrospective Studies; Surgeons; | 2023 |
Factor XIII deficiency leading to preseptal haematoma post-strabismus surgery.
Topics: Antifibrinolytic Agents; Child; Exotropia; Eyelid Diseases; Factor XIII Deficiency; Female; Hematoma | 2019 |
Noncontrast Computed Tomography Signs as Predictors of Hematoma Expansion, Clinical Outcome, and Response to Tranexamic Acid in Acute Intracerebral Hemorrhage.
Topics: Aged; Cerebral Hemorrhage; Cohort Studies; Disease Progression; Female; Hematoma; Humans; Logistic M | 2020 |
Topics: Aged, 80 and over; Airway Obstruction; Antifibrinolytic Agents; Cyclophosphamide; Glucocorticoids; H | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Discussion: Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Antifibrinolytic Agents; Hematoma; Humans; Mammaplasty; Thromboembolism; Tranexamic Acid | 2020 |
Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Platelets; Factor V Deficiency; Fibrinol | 2020 |
Hockey: a pain in the butt! Isolated superior gluteal artery rupture following blunt pelvic trauma - an unusual case.
Topics: Aneurysm, False; Antifibrinolytic Agents; Buttocks; Computed Tomography Angiography; Embolization, T | 2021 |
Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report.
Topics: Adenocarcinoma; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; Blood Coagulation | 2016 |
Pre-hospital care in stroke: A technological revolution.
Topics: Ambulances; Databases, Factual; Emergency Medical Services; Factor VIIa; Health Information Exchange | 2018 |
Examining the use of intraoperative tranexamic acid in oncoplastic breast surgery.
Topics: Antifibrinolytic Agents; Breast Neoplasms; Female; Hematoma; Humans; Mammaplasty; Mastectomy; Retros | 2019 |
Tranexamic acid decreases risk of haematomas but not pain after hip arthroplasty.
Topics: Adult; Aged; Analgesics, Opioid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss | 2013 |
Utility of thromboelastography in managing acquired Factor VIII inhibitor associated massive haemorrhage.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Transfusion; Endometrial Neoplasms; Factor | 2013 |
Bleeding complications during cardiac electronic device implantation in patients receiving antithrombotic therapy: is there any value of local tranexamic acid?
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Chi-Square Distributio | 2016 |
Orbital subperiosteal hematoma after thrombolysis and anticoagulation for acute myocardial infarction.
Topics: Accidental Falls; Acute Disease; Adult; Anticoagulants; Antifibrinolytic Agents; Craniocerebral Trau | 2009 |
Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage.
Topics: Animals; Anticoagulants; Blood Coagulation Factors; Cerebral Hemorrhage; Collagenases; Disease Model | 2011 |
Giant abdominopelvic haematoma arising from ovulation in a Glanzmann's thrombasthenia patient with platelet refractoriness: treatment with surgery and intra-abdominal tranexamic acid.
Topics: Adult; Corpus Luteum; Female; Hematoma; Humans; Ovarian Cysts; Ovulation; Rupture, Spontaneous; Thro | 2012 |
Combination therapy of DDAVP and conjugated estrogens for a recurrent large subcutaneous hematoma in Ehlers-Danlos syndrome.
Topics: Adrenochrome; Adult; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Dru | 2003 |
Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Blood Pressure; Case-Control Studies; Cerebral Hemo | 2005 |
The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia.
Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Dental Care for Chronically Ill | 2007 |
Bleeding tendency caused by the deposit of amyloid substance in the perivascular region.
Topics: Adrenochrome; Amyloid; Amyloidosis; Blood Vessels; Female; Hematoma; Hemostatics; Humans; Middle Age | 1993 |
Operative treatment of intramedullary hematoma associated with congenital deficiency of alpha 2-plasmin inhibitor, A report of three cases.
Topics: Adolescent; alpha-2-Antiplasmin; Antifibrinolytic Agents; Bone Marrow Diseases; Child; Curettage; Du | 1996 |
Severe hemorrhage after implant surgery.
Topics: Adult; Airway Obstruction; Antifibrinolytic Agents; Dental Implantation, Endosseous; Hematoma; Human | 1999 |
Treatment of subdural and intracerebral haematomas in a haemodialysis patient with tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Hematoma; Hematoma, Subdural; Humans; Intracranial Hemorrhages; Male; | 2000 |
An unusual cause of bleeding.
Topics: Adult; Amyloidosis; Antifibrinolytic Agents; Female; Hematoma; Humans; Tranexamic Acid | 2001 |
Intramedullary multiple hematomas in siblings with congenital alpha-2-plasmin inhibitor deficiency: orthopedic surgery with protection by tranexamic acid.
Topics: Adolescent; alpha-2-Antiplasmin; Blood Loss, Surgical; Bone Diseases; Child; Female; Femur; Hematoma | 1991 |
Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
Topics: alpha-2-Antiplasmin; Amyloidosis; Antifibrinolytic Agents; Fibrin Fibrinogen Degradation Products; F | 1986 |
Oral nimodipine reduces prostaglandin and thromboxane production by arteries chronically exposed to a periarterial haematoma and the antifibrinolytic agent tranexamic acid.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Carotid Arteries; Cyclohexanecarboxylic Acids; Dinoprost; Din | 1987 |